Skip to main content
SpringerLink
Log in

Minimize and manage the occurrence of chemotherapy-induced nausea and vomiting with a carefully selected prophylactic regimen

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Nausea and vomiting that are induced by chemotherapy have a negative impact on the health-related quality of life of affected patients, can cause potentially serious complications and may deter patients from further chemotherapy treatment. Appropriate use of prophylactic regimens may help to minimize the incidence of such nausea and vomiting. Selection of prophylaxis should be based on patient- and chemotherapy-related factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs. 2013;73(3):249–62.

    Article  PubMed  Google Scholar 

  2. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): antiemesis (version 1.2013). Fort Washington: National Comprehensive Cancer Network®, Inc., 2012.

  3. Morrow GR, Roscoe JA, Kirshner JJ, et al. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer. 1998;6(3):244–7.

    Article  PubMed  CAS  Google Scholar 

  4. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(Suppl 5):v232–43.

    Article  PubMed  Google Scholar 

  5. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189–98.

    Article  PubMed  Google Scholar 

  6. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98(11):2473–82.

    Article  PubMed  CAS  Google Scholar 

  7. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14(10):1570–7.

    Article  PubMed  CAS  Google Scholar 

  8. Aogi K, Sakai H, Yoshizawa H, et al. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer. 2012;20(7):1507–14.

    Article  PubMed  Google Scholar 

  9. Longo F, Mansueto G, Lapadula V, et al. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int J Clin Pract. 2012;66(8):753–7.

    Article  PubMed  CAS  Google Scholar 

  10. Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol. 2011;29(11):1495–501.

    Article  PubMed  CAS  Google Scholar 

  11. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer. 2005;13(7):529–34.

    Article  PubMed  Google Scholar 

  12. Navari RM, Einhorn LH, Loehrer PJ Sr, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007;15(11):1285–91.

    Article  PubMed  Google Scholar 

  13. Tan L, Liu J, Liu X, et al. Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 2009;28:131.

    Article  PubMed  Google Scholar 

  14. Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013;21(6):1655–63.

    Article  PubMed  Google Scholar 

  15. Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23(3):533–43.

    Article  PubMed  CAS  Google Scholar 

  16. Fein LE, Poma A, Hedley ML. Efficacy and safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting in subjects receiving highly emetogenic chemotherapy [abstract no. 9077]. J Clin Oncol. 2012;30(15 Suppl).

  17. Rossi G, Tilkola SO, Rudengren C. A positron emission tomography study to assess the degree of neurokinin-1 receptor occupancy in the human brain after single doses of netupitant to healthy male subjects [abstract no. 9054]. J Clin Oncol. 2012;30 (15 Suppl).

  18. Cruz FM, de Iracema Gomes Cubero D, Taranto P, et al. Gabapentin for the prevention of chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer. 2012;20(3):601–6.

Download references

Disclosure

This article was adapted from Drugs 2013;73(3):249–62 [1]. The preparation of these articles was not supported by any external funding.

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Cite this article

    Adis Medical Writers. Minimize and manage the occurrence of chemotherapy-induced nausea and vomiting with a carefully selected prophylactic regimen. Drugs Ther Perspect 29, 210–214 (2013). https://doi.org/10.1007/s40267-013-0049-5

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-013-0049-5

    Keywords

    Search

    Navigation